The Emerging Scenario of the Onco-Cardiovascular Patients

Abstract

Cardiotoxicity prevention remains an important challenge in the emerging scenario of the onco-cardiovascular patients. New targeted anticancer therapies haven’t proven to be free from cardiovascular side effects while old anticancer therapies provide us with delayed serious consequences in long term cancer survivors. There is a need for large studies to clear apparently conflicting observations and to expand the evidence base in cardio-oncology promoting new strategies for patients’ safety and to encourage the patients in their heavy cancer journey avoiding communication breakdowns.